{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:22:23Z","timestamp":1790216543314,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1136\/ijgc-2024-005361","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:10:45Z","timestamp":1717182645000},"page":"1232-1239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2905-5947","authenticated-orcid":false,"given":"Stefano","family":"Durante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caminiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1936","authenticated-orcid":false,"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Vigorito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ferrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Chiantera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005361_bb0010","first-page":"198","article-title":"Management of recurrent epithelial ovarian cancer","volume":"3","author":"Vargas-Hern\u00e1ndez","year":"2014","journal-title":"Gland Surg"},{"key":"10.1136\/ijgc-2024-005361_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00177","article-title":"Radiation treatment in women with ovarian cancer: past, present, and future","volume":"7","author":"Fields","year":"2017","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.clon.2018.06.001","article-title":"Radiation therapy in ovarian cancer: an overview and future directions","volume":"30","author":"McCormack","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1136\/ijgc-2024-005361_bb0025","article-title":"Is it time to reassess the role of radiotherapy treatment in ovarian cancer","volume":"11","author":"Macchia","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1136\/ijgc-2024-005361_bb0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/ijgc-2022-004149","article-title":"Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005361_bb0035","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005361_bb0040","article-title":"Ep233\/#541 patterns of initial ovarian cancer recurrence on Niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA\/ENGOT-OV26\/GOG-3012 post-hoc subgroup analysis","volume":"32","author":"Kamavra","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005361_bb0045","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00432-020-03223-9","article-title":"Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases","volume":"146","author":"Nicosia","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.rpor.2014.11.005","article-title":"SBRT for lung oligometastases: who is the perfect candidate?","volume":"20","author":"Navarria","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1136\/ijgc-2024-005361_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.euo.2019.08.012","article-title":"Progression-directed therapy for oligoprogression in castration-refractory prostate cancer","volume":"4","author":"Berghen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0060","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.21037\/apm.2020.03.31","article-title":"Oligometastases: history of a hypothesis","volume":"10","author":"Milano","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1136\/ijgc-2024-005361_bb0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2024-005361_bb0070","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/ijgc-2023-004740","article-title":"Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005361_bb0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijrobp.2019.11.009","article-title":"Oligoreview of non-small cell lung cancer oligometastases","volume":"106","author":"Giuliani","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2024-005361_bb0085","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ygyno.2018.07.002","article-title":"Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas","volume":"150","author":"Bi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0090","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or Immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO Oligocare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2024-005361_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005361_bb0105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local Consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0110","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO Rt1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2024-005361_bb0115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2020.08.010","article-title":"Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: a systematic review","volume":"159","author":"Yegya-Raman","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0130","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1007\/s00432-021-03802-4","article-title":"The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes","volume":"147","author":"Cuccia","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0135","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","article-title":"Stereotactic body radiation therapy in oligometastatic ovarian cancer: a promising therapeutic approach","volume":"28","author":"Iftode","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005361_bb0140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiotherapy for oligometastatic ovarian cancer: a step towards a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2024-005361_bb0145","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","volume":"32","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005361_bb0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0155","article-title":"Recursive partitioning analysis for local control achieved with stereotactic body radiation therapy for the liver, spine, or lymph nodes","volume":"6","author":"Kowalchuk","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0160","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clon.2023.07.011","article-title":"Stereotactic body reirradiation in gynaecological cancer: outcomes and toxicities from a single institution experience","volume":"35","author":"Macchia","year":"2023","journal-title":"Clin Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0165","doi-asserted-by":"crossref","first-page":"1021058","DOI":"10.3389\/fonc.2022.1021058","article-title":"Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration","volume":"12","author":"Cao","year":"2023","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0170","article-title":"Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: a sharp tool to prolong the interval of systemic treatment","volume":"13","author":"Shen","year":"2022","journal-title":"Discov Oncol"},{"key":"10.1136\/ijgc-2024-005361_bb0175","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","article-title":"Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-Rt3\/RAD)","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:26:17Z","timestamp":1764062777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1048891X24000100"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005361","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}